アブストラクト
| Title | バンコマイシン |
|---|---|
| Subtitle | 特集 抗菌薬TDM臨床実践ガイドライン2022はここに注目! 新旧抗菌薬の使い方 ここが変わった抗菌薬のTDM |
| Authors | 松元一明 |
| Authors (kana) | |
| Organization | 慶應義塾大学薬学部薬効解析学講座 |
| Journal | 月刊薬事 |
| Volume | 64 |
| Number | 7 |
| Page | 1347-1350 |
| Year/Month | 2022 / 5 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | [Key Points] ●安全性の観点からAUCを指標とする. ●目標AUCは400〜600μg・h/mLである. ●初回TDMは定常状態前の2日目に行う. ●トラフ値とピーク値を用いてAUCを評価する. ●Practical AUC-guided TDM(PAT)など日本人母集団薬物動態パラメータを用いたソフトウエアの使用が勧められる. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) Rybak MJ : The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis, 42(Suppl. 1) : S35-S39, 2006
- 2) Pais GM, et al : Comparative performance of urinary biomarkers for vancomycin-induced kidney injury according to timeline of injury. Antimicrob Agents Chemother, 63 : e00079-19, 2019
- 3) Avedissian SN, et al : Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model. J Antimicrob Chemother, 74 : 2326-2334, 2019
- 4) Tsutsuura M, et al : The monitoring of vancomycin : a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing. BMC Infect Dis, 21 : 153, 2021
- 5) Yanagihara K, et al : Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2012 : General view of the pathogens' antibacterial susceptibility. J Infect Chemother, 23 : 587-597, 2017
残りの19件を表示する
- 6) Takesue Y, et al : Antimicrobial susceptibility of pathogens isolated from surgical site infections in Japan : Comparison of data from nationwide surveillance studies conducted in 2010 and 2014-2015. J Infect Chemother, 23 : 339-348, 2017
- 7) Hanaki H, et al : Antibiotic susceptibility survey of blood-borne MRSA isolates in Japan from 2008 through 2011. J Infect Chemother, 20 : 527-534, 2014
- 8) Tsuji BT, et al : Evaluation of accessory gene regulator(agr)group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus. Antimicrob Agents Chemother, 51 : 1089-1091, 2007
- 9) Vidaillac C, et al : Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant Staphylococcus aureus. J Infect Dis, 208 : 67-74, 2013
- 10) Singh NB, et al : Impact of cefazolin co-administration with vancomycin to reduce development of vancomycin-inter-mediate Staphylococcus aureus. Diagn Microbiol Infect Dis, 91 : 363-370, 2018
- 11) Gawronski KM, et al : A stewardship program's retro-spective evaluation of vancomycin AUC24/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. Clin Ther, 35 : 772-779, 2013
- 12) Rees MR, et al : Outpatient vancomycin therapy : Acute kidney injury in individualized AUC-based goal trough ranges versus traditional trough dosing. J Am Pharm Assoc (2003), S1544-3191(21)00492-1, 2021
- 13) Clark L, et al : Examining the relationship between vancomycin area under the concentration time curve and serum trough levels in adults with presumed or documented staphylococcal infections. Ther Drug Monit, 41 : 483-488, 2019
- 14) Kamel AB, et al : Is trough concentration of vancomycin predictive of the area under the curve? A clinical study in elderly patients. Ther Drug Monit, 39 : 83-87, 2017
- 15) Pai MP, et al : Innovative approaches to optimizing the delivery of vancomycin in individual patients. Adv Drug Deliv Rev, 77 : 50-57, 2014
- 16) Neely MN, et al : Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother, 58 : 309-316, 2014
- 17) Oda K, et al : Performance of area under the concentration-time curve estimations of vancomycin with limited sampling by a newly developed web application. Pharm Res, 38 : 637-646, 2021
- 18) Shime N, et al : The importance of a judicious and early empiric choice of antimicrobial for methicillin-resistant Staphylococcus aureus bacteraemia. Eur J Clin Microbiol Infect Dis, 29 : 1475-1479, 2010
- 19) Lodise TP, et al : Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections : how much is enough? Clin Infect Dis, 59 : 666-675, 2014
- 20) Casapao AM, e t al : Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis. Antimicrob Agents Chemother, 59 : 2978-2985, 2015
- 21) Ueda T, et al : Validation of vancomycin area under the concentration-time curve estimation by the Bayesian approach using one-point samples for predicting clinical outcomes in patients with methicillin-resistant Staphylococcus aureus infections. Antibiotics(Basel), 11 : 96, 2022
- 22) Lodise TP, et al : The Emperor's New Clothes : Prospective observational evaluation of the association between initial vancomycin exposure and failure rates among adult hospitalized patients with methicillin-resistant Staphylococcus aureus bloodstream infections(PROVIDE). Clin Infect Dis, 70 : 1536-1545, 2020
- 23) 新沼悠介, 他 : 腎機能低下患者へのバンコマイシン初回負荷投与の安全性調査. TDM研究, 36 : 117-124, 2019
- 24) Hashimoto N, et al : Candidates for area under the concen-tration-time curve(AUC)-guided dosing and risk reduction based on analyses of risk factors associated with nephrotoxicity in vancomycin-treated patients. J Glob Antimicrob Resist, 27 : 12-19, 2021
